GILUPI GmbH

GILUPI GmbH is a biotechnology startup based in Germany that focuses on advancing diagnostic procedures for precision medicine, particularly in the field of oncological diagnostics. Since its establishment in 2006, GILUPI GmbH has been developing new diagnostic products for in vivo isolation of rare cells from the blood, with a current emphasis on the oncological diagnostics market. The company's flagship product, the GILUPI CellCollector®, has obtained CE certification and is the first approved product utilizing this innovative technology. It enables the enrichment of rare target cells, such as circulating tumor cells, directly from the bloodstream. These cells can then be characterized and analyzed at a molecular level using various diagnostic methods, allowing for the observation of patients during and after cancer treatment. Personalized oncological therapies are expected to gain significant clinical value in the coming years, and the accurate identification of the right medication for each patient will be crucial. The GILUPI CellCollector® addresses this need by providing simple and minimally invasive cell isolation, offering valuable insights into the patient's current disease status. This diagnostic information can potentially guide treatment adjustments or facilitate the selection of optimal therapies by physicians. The company received a €3.60M Series C investment on 13 January 2011, with participation from High-Tech Gründerfonds, KfW, and BC Brandenburg Capital. With its innovative approach to precision medicine and the successful development of its pioneering product, GILUPI GmbH is well-positioned to make significant contributions to the field of oncological diagnostics and personalized medicine.